425 related articles for article (PubMed ID: 19714594)
21. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
22. Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.
Liegel J; Courville E; Sachs Z; Ustun C
Haematologica; 2014 Nov; 99(11):e222-4. PubMed ID: 25015937
[No Abstract] [Full Text] [Related]
23. [FLT3 internal tandem duplication in patients with acute promyelocytic leukemia].
Zhu YM; Liu YF; Zhang SJ; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2007 Jun; 28(6):371-4. PubMed ID: 17939400
[TBL] [Abstract][Full Text] [Related]
24. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
Pinheiro RF; de Sá Moreira E; Silva MR; Alberto FL; Chauffaille Mde L
Cancer Genet Cytogenet; 2008 Jun; 183(2):89-93. PubMed ID: 18503825
[TBL] [Abstract][Full Text] [Related]
25. Investigational drugs targeting FLT3 for leukemia.
Ustun C; DeRemer DL; Jillella AP; Bhalla KN
Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
[TBL] [Abstract][Full Text] [Related]
26. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
[No Abstract] [Full Text] [Related]
27. [Progression of sorafenib in the treatment of acute myeloid leukemia].
Zhou XJ; Zhang SJ; Shen YF
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):352-4. PubMed ID: 21729611
[No Abstract] [Full Text] [Related]
28. [All-trans retinoic acid was effective for marked skin infiltration in a relapsed acute myelogenous leukemia (AML-M2) patient with t(12; 17)].
Sawanobori M; Nakagawa Y; Inoue Y; Suzuki K; Kanno K; Hashimoto S; Takemura T
Rinsho Ketsueki; 1998 May; 39(5):363-8. PubMed ID: 9637886
[TBL] [Abstract][Full Text] [Related]
29. [Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].
Jiang ZH; Feng FE; Lin XQ; Lu J
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):736. PubMed ID: 23978034
[No Abstract] [Full Text] [Related]
30. Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
von Bubnoff N; Rummelt C; Menzel H; Sigl M; Peschel C; Duyster J
Leukemia; 2010 Aug; 24(8):1523-5. PubMed ID: 20520641
[No Abstract] [Full Text] [Related]
31. [Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option].
Metzelder SK; Wollmer E; Neubauer A; Burchert A
Dtsch Med Wochenschr; 2010 Sep; 135(38):1852-6. PubMed ID: 20740398
[TBL] [Abstract][Full Text] [Related]
32. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Pratz KW; Cho E; Levis MJ; Karp JE; Gore SD; McDevitt M; Stine A; Zhao M; Baker SD; Carducci MA; Wright JJ; Rudek MA; Smith BD
Leukemia; 2010 Aug; 24(8):1437-44. PubMed ID: 20535150
[TBL] [Abstract][Full Text] [Related]
33. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
Fathi AT; Lin WM; Durazzo T; Piris A; Sadrzadeh H; Bernardo L; Borger DR; McAfee SL; Kroshinsky D; Chen YB
J Clin Oncol; 2016 Mar; 34(8):e70-2. PubMed ID: 25024084
[No Abstract] [Full Text] [Related]
34. Molecular variability of FLT3/ITD mutants and their impact on the differentiation program of 32D cells: implications for the biological properties of AML blasts.
Pekova S; Ivanek R; Dvorak M; Rueggeberg S; Leicht S; Li X; Franz T; Kozak T; Vrba J; Koza V; Karas M; Schwarz J; Cetkovsky P; Prucha M
Leuk Res; 2009 Oct; 33(10):1409-16. PubMed ID: 19181379
[TBL] [Abstract][Full Text] [Related]
35. Images in clinical medicine. FLT3 Mutation and acute myelogenous leukemia with leukostasis.
Thornton KA; Levis M
N Engl J Med; 2007 Oct; 357(16):1639. PubMed ID: 17942876
[No Abstract] [Full Text] [Related]
36. Aberrant expression of CD7 in acute myeloid leukemias with FLT3-ITD.
Juncà J; Zamora L; Cabezón M; Marcè S; Nomdedéu J
Am J Clin Pathol; 2008 Oct; 130(4):644; author reply 645. PubMed ID: 18825844
[No Abstract] [Full Text] [Related]
37. Mutated gene markers predict outcome for patients with AML.
McBride D
ONS Connect; 2012 May; 27(5):21. PubMed ID: 22690521
[No Abstract] [Full Text] [Related]
38. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
Tollkuci E
J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838
[TBL] [Abstract][Full Text] [Related]
39. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
[TBL] [Abstract][Full Text] [Related]
40. SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia.
van der Werf I; Wojtuszkiewicz A; Yao H; Sciarrillo R; Meggendorfer M; Hutter S; Walter W; Janssen J; Kern W; Haferlach C; Haferlach T; Jansen G; Kaspers GJL; Groen R; Ossenkoppele G; Cloos J
Leukemia; 2021 Sep; 35(9):2698-2702. PubMed ID: 34002025
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
